6 patients (19.4%) RC. In Kaplan-Meier analysis, patients with MIBC had better median overall survival with curative treatment compared to TURBT alone (28 vs. 9 months; p < 0.001, log-rank test). Conclusions: By offering a wide range of treatment options, over 43% of octogenarians with MIBC received a curative therapy at a maximum care hospital.
Introduction
Urothelial carcinoma of the bladder (UCB) is the ninth most common cancer worldwide, with an estimate of 429,000 cases in 2012. Fifty-nine percent of UCB cases occur in developed countries [1] . Like many other cancers, the incidence of UCB increases with age. The median age at diagnosis is 73 years, and the peak incidence of bladder cancer occurs at 85 years [2, 3] . Approximately 75% of all newly diagnosed UCB cases are non-muscle invasive tumors (NMIBCs), and the remaining are muscle invasive [4] . A radical cystectomy (RC) remains the treatment of choice for muscle invasive bladder cancer (MIBC) [5] . Although several studies have demonstrated the safety and survival benefit of RC, even in elderly patients [6] [7] [8] [9] , there is still hesitancy to perform a RC be-cause of the comorbidities and frailty of this population [2, 10] . Other less aggressive options, such as a transurethral resection of the bladder tumor (TURBT) or radiotherapy (RT), are often preferred for elderly patients [11, 12] . However, high-grade NMIBC and MIBC in particular are very likely to progress. The 5-year survival rate for patients with MIBC is reported to be as low as 6% [13] . Moreover, bladder cancer is the fourth leading cause of cancer-related deaths for men aged ≥ 80 years [14] . However, it has to be considered that the life expectancy in developed countries for 80-year-old white women is 8-9 years and for 80-year-old white men 6-7 years [15] ; thus, considering the right treatment options for patients of this age is necessary.
In our study, we retrospectively analyzed how octogenarians are treated in a maximum care hospital that offers a wide variety of treatment options.
Materials and Methods
This retrospective study was approved by the Ethics Committee of the Friedrich-Alexander University Erlangen-Nuremberg. No informed consent was obtained since most of the participants had already passed away at the time of this study. Patient information was anonymized and de-identified prior to analysis.
The present study was a single-center analysis. We retrospectively analyzed treatment modalities of all the patients aged ≥ 80 years with UCB who were treated at the University Hospital in Erlangen, Germany, between 1982 and 2011. Treatments were performed by the Department of Urology in close cooperation with the Department of Radiation Oncology. Common treatment options offered by the Department of Urology included bladdersparing options, such as a TURBT and local instillation of mitomycin or bacillus Calmette-Guérin (BCG), as well as RC with various urinary diversions, such as ileum-conduit, neo-bladder or pouches.
The Department of Radiation Oncology at the University Hospital in Erlangen is a transregional center for bladder-preserving treatments for bladder cancer. They offer RT of the bladder, radiochemotherapy (RCT) and, in some cases, these treatments in combination with deep regional hyperthermia. RT or RCT was initiated 4-8 weeks after the initial TURBT using 6-to 10-mV photons and a 4-field box technique with individually shaped portals and daily fractions of 1.8-2.0 Gy on 5 consecutive days. The bladder was irradiated with a median total dose of 54 Gy while the pelvis was irradiated with a median total dose of 45 Gy [16] . Whenever RCT was possible, chemotherapy was applied simultaneously during the first and fifth week of RT on 5 consecutive days and consisted of cisplatin 20 mg/m 2 /day and 5-fluoruracil 600 mg/m 2 /day. In patients ineligible for cisplatin, carboplatin 65 mg/ m 2 /day was used instead [16] . In some cases, deep regional hyperthermia was applied additionally on day 1 of every week during RCT. The treatment algorithm for RCT used at the University Hospital Erlangen has been previously described in greater detail [16] [17] [18] .
For the analysis, the patients were divided into 2 groups: NMIBC (pTa, pT1, CIS) and MIBC (pT2-pT4). Overall survival and disease-specific survival rates of the patients who received TURBT only or an additional treatment after TURBT were analyzed using a Kaplan-Meier method and compared using a logrank test. All tests were 2-sided, and p values <0.05 were considered to be statistically significant. Statistical analyses were performed with SPSS version 21.0 (IBM, Chicago, Ill., USA).
Results
A total of 276 patients aged ≥ 80 years were treated at the University Hospital in Erlangen between 1982 and 2011. NMIBC (pTa, pT1, CIS) was diagnosed in 146 of the patients (52.9%), while 71 of the patients (25.7%) had pT2-pT4 tumors. There were no data on the tumor stage for 59 of the patients (21.4%).
Every patient received TURBT for diagnostic and therapeutic purposes, and 58.2% of the patients with NMIBC (85 of 146 patients) received only follow-ups after the initial TURBT. Twenty-six percent of the patients (38 of 146 patients) underwent an additional intravesical therapy with either mitomycin (36 patients) or BCG (2 patients). Thirteen patients (8.9%) were treated with RCT, 6 patients (4.1%) with RT alone and 2 patients with systemic chemotherapy (1.4%). Two patients with locally wide-spread NMIBC (1.4%) were treated with RC.
The patients with MIBC received regular follow-ups or watchful waiting after the initial TURBT in 54.9% of the cases (39 of 71 patients). One patient (1.4%) received systemic chemotherapy. Of the patients with MIBC, 43.7% (31 of 71 patients) were treated with a potentially curative therapy approach. Out of these, 51.6% (16 of 31 patients) received a trimodality therapy with a TURBT and RCT, 29.0% (9 of 31 patients) received a TURBT followed by RT alone and in 19.4% (6 of 31 patients) RC with urinary diversion was performed.
When analyzing the long-term survival, we discovered that the patients with MIBC exhibited a clear survival benefit when they received a potentially curative treatment compared to the patients who underwent TURBT only ( fig. 1 ). This survival benefit was most pronounced in overall survival. The patients who only underwent watchful waiting had a median overall survival of 9 months, whereas the patients who underwent a potentially curative treatment exhibited a median overall survival of 28 months (p < 0.001, log-rank test). Interestingly, for the patients with NMIBC, the treatment modality (follow-up vs. instillation, RCT, RT or RC) had no significant impact on the long-term prognosis ( fig. 2 
Discussion
Untreated advanced bladder cancer patients have poor outcomes. The treatment of choice with the best cancerspecific survival is a RC with a lymphadenectomy and urinary diversion [19] . Even for elderly patients, cystectomy seems to be a relatively safe treatment option as there is no increased rate of perioperative complications compared with younger patients, while overall survival is improved [6, 7] . Comorbidity indices like the Charlson comorbidity index can help to assess the patients best suited for surgery and to predict the outcome after RC [20] . In multimorbid patients, the surgical risk of RC can further be reduced by performing ureterocutaneostomy instead of urinary diversions with bowel segments [21] . Nevertheless, the rate of RC in elderly patients is relatively low. Prout et al. [2] 265 ceived a RC, while this rate was 55% in patients aged 55-59 years. In addition to age, their study showed that the possibility of having a cystectomy is also reduced by an increasing ASA score. In addition to age and comorbidities, another reason for the reluctance to perform a RC may be the complexity of performing a RC. Performing RC with urinary diversion is a very challenging procedure that has many perioperative risks, such as upper urinary tract obstruction, acidosis or ileus, especially in frail patients with comorbidities [22, 23] . The rate of perioperative complications depends not only on the age and general health of the patient but also on a clinic's caseload and surgeon's experience. Several studies have shown a lower perioperative morbidity and mortality in high volume hospitals with experienced surgeons [24, 25] . These factors may result in choosing a less aggressive treatment option, such as a TURBT alone or with BCG instillation or watchful waiting. Although these treatment options have fewer complications than a RC initially, the complications increase over time. Even in highly selected patient groups, both MIBC recurrence and tumor progression occur in 30% of patients with MIBC treated with TURBT alone [26] . BCG instillation therapy has a lower response in elderly patients and a higher rate of complications, such as bladder pain, voiding symptoms and fever [27, 28] . When considering that the life expectancy of healthy octogenarians is 6-9 years [15] , physicians should aim for a more aggressive and potentially curative treatment option whenever possible.
In our cohort, 54.9% of octogenarians with MIBC received a TURBT alone followed either by regular followup or watchful waiting. This number was quite low compared to other studies. Prout et al. [2] showed that 76% of patients aged ≥ 75 years with MIBC were treated with TURBT alone. Hollenbeck et al. [6] showed by analyzing the SEER database that 79.0% of octogenarians with bladder cancer received a TURBT alone as the primary treatment and 7.3% received watchful waiting only. While there are some discrepancies between these and our own population (Prout et al. [2] used an age cutoff ≥ 75 years, while Hollenbeck et al. [6] did not distinguish between radical and partial cystectomies), the percentage of RC for octogenarians with MIBC seems lower in our cohort (8.5% compared to 14 and 18.7%, respectively) than one might expect at a maximum care hospital with a high caseload. Nevertheless, by offering RCT or RT to patients unfit for RC, a total of 43.7% of octogenarians with MIBC were treated with a potentially curative treatment option. The European Association of Urology Guidelines recommends multimodality therapy consisting of a maximal TURBT followed by RT alone or in combination with chemotherapy as an alternative treatment option for patients suffering from UCB, especially when RC is not an option [29] . While there are no prospective randomized controlled trials comparing the outcome of RCT to RC and a direct comparison between the existing series is not possible because of different study criteria, RCT seems to be a valid treatment option for patients with high-risk NMIBC and MIBC and has comparable long-term overall survival rates to a RC [30, 31] . With RCT following TURBT, 5-year disease specific survival rates ranging from 50 to 82% and overall survival rates from 36 to 74% can be achieved, with salvage cystectomy rates of 25-30% [32] . Efstathiou et al. [31] demonstrated in a prospective analysis that the 5-and 10-year disease-specific survival was 74 and 67% for T2 tumors and 53 and 49% for T3-T4 tumors, respectively, if the patients showed a complete response to the initial TURBT and RCT. Moreover, the long-term survival outcome for patients with T1G3 tumors seems to be superior with TURBT followed by RCT compared to TURBT followed by BCG. However, prospective randomized trials comparing these treatment options for high-risk NMIBC are still lacking and thus RCT is not regarded as the standard treatment in this population [33] .
Data regarding the distribution of bladder-sparing multimodality therapy in patients with MIBC is scarce, especially in octogenarians. The analysis of a linked SEER/ Medicare database revealed that out of 3,262 patients aged ≥ 66 years with MIBC, 271 (8.3%) received RT alone, while 249 (7.6%) received RCT [34] . Out of the 1,555 octogenarians in this population, 427 were treated either by chemotherapy, RT or RCT. However, no information regarding the exact type of therapy was provided in this study [34] . A recent analysis of the National Cancer Data Base revealed that RCT or RT was used in 7.6% of the patients with MIBC in the United States. These number increases to around 11% for patients aged 81-90 years [35] . In our analysis, 22.5% of the octogenarians with MIBC received RCT, and 12.7% received RT alone. The preferred use of RCT in our population is important because significantly better disease-specific survival has been shown for RCT compared to RT alone [36] . However, not all patients are suitable for chemotherapy, due to reduced performance status or comorbidities, such as renal insufficiency. It also has to be considered that even bladdersparing approaches are associated with side effects, such as a risk of local recurrence, shrinkage of the bladder and other radiation-associated side effects [37] . To achieve better patient selection for bladder-sparing multimodality therapy, especially in the potentially more vulnerable population of octogenarians, the clinical implementation of promising molecular predictive biomarkers such as ERCC1, VEGF-C and neuropilin-2 needs to be further validated [38] [39] [40] .
There are several limitations to our study that need to be addressed. Most notable is the relatively small percentage of RCs performed on octogenarians at our center, which might open us to criticism. The University Hospital Erlangen is a transregional center for RT of UCB, meaning that patients get specifically referred to our center to receive bladder-sparing treatment options. This may result in a shift of treatment options toward radiotherapeutic therapies to the disadvantage of RC. The situation at our hospital does not represent the situation at a regular German hospital. RTs or RCTs are usually seldom offered as regular therapeutic options for bladder cancer in German hospitals and are not even considered a valid treatment option by many urologic surgeons. Yet the previously cited studies [2, 6] prove that the risk of getting only watchful waiting or an insufficient therapy does increase with age. In our study, octogenarians with MIBC receiving a potentially curative treatment approach clearly exhibited a significantly improved overall and disease-specific survival, implicating the benefit of more aggressive treatment over a TURBT alone. While these results do not challenge the significance of RC as the gold standard for the treatment of octogenarians with MIBC deemed fit for surgery in any way, a wider distribution of radiotherapeutic options or a referral to a specialized center can offer a chance to guarantee optimal care for patients not fit for surgery, as the factors that determine fitness for RC and RCT differ [29] .
Interestingly, no survival benefit was seen when comparing octogenarians with superficial UCB who only obtained a follow-up compared to other treatment options. Reasons for this might be an understaging of a proportion of the superficial bladder cancers and the inclusion of all NMIBC stages into one mixed cohort.
Another limitation is the retrospective nature of this analysis, as we only had limited information regarding the health status and comorbidities of the patients. Therefore, the decision-making process for the individual treatments cannot be reconstructed. The lack of clinical data on patients' health status as well as the long recruitment period is the main reason why a direct comparison of survival between the different treatment modalities is not possible. Therefore further analyses stratified for patient comorbidities are warranted to gain further insights into the value of different treatment options for elderly patients. Nevertheless, a reduced health status due to age and additional comorbidities is to be expected when treating octogenarians, which is also the most likely reason as to why so few octogenarians received curative treatment approaches according to previous studies. However, by offering a wider range of treatment options, it was possible to provide a curative treatment option to more than 43% of octogenarians with MIBC at our maximum care hospital.
Conclusion
In the light of an aging population, our analysis showed that by offering a wide range of treatment options and interdisciplinary collaboration, it is possible to offer a potentially curative treatment option to over 43% of octogenarians with MIBC. Still, because of its proven safety even for octogenarians, an increase in the rate of RC should be sought.
